Eyenovia, Inc. (EYEN)
NASDAQ: EYEN · Real-Time Price · USD
0.487
-0.014 (-2.72%)
At close: Nov 7, 2024, 4:00 PM
0.490
+0.003 (0.70%)
After-hours: Nov 7, 2024, 6:56 PM EST
Eyenovia Revenue
Eyenovia had revenue of $22.63K in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $31.41K. In the year 2023, Eyenovia had annual revenue of $3.79K.
Revenue (ttm)
$31.41K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
$551
Employees
57
Market Cap
42.03M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Inotiv | 501.06M |
HOOKIPA Pharma | 52.16M |
Allurion Technologies | 47.59M |
iCAD, Inc. | 18.80M |
Accelerate Diagnostics | 12.23M |
VYNE Therapeutics | 486.00K |
Daxor | 154.21K |
Incannex Healthcare | 12.00K |
EYEN News
- 12 hours ago - Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th - GlobeNewsWire
- 22 days ago - Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo - GlobeNewsWire
- 5 weeks ago - Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device - GlobeNewsWire
- 5 weeks ago - Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering - GlobeNewsWire
- 6 weeks ago - Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery - GlobeNewsWire
- 2 months ago - Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization - PRNewsWire
- 2 months ago - Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S. - GlobeNewsWire
- 2 months ago - Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer - GlobeNewsWire